景峯醫藥(000908.SZ):2019年由盈轉虧 淨虧損8.83億元
格隆匯4月30日丨景峯醫藥(000908.SZ)披露2019年年度報告,報告期內,公司實現營業收入13.44億元,同比下降48.02%;歸屬於上市公司股東的淨虧損8.83億元,而上年同期為盈利1.87億元;經營活動現金淨流入3617.04萬元,同比下降89.69%;基本每股虧損1.0034元。
報告期內,營業收入發生重大變化主要受2019年醫保控費、重點監控、輔助用藥等政策影響。在此整體不利環境和形勢下,公司的生產經營受到重大不利影響,造成經營業績大幅下滑。尤其是注射劑產品的收入較上年同期下滑達70.31%,注射劑產品收入佔總收入的佔比也由2018年的69.16%下降到39.5%。公司對商譽計提減值準備影響公司淨利潤3.05億元,歸屬於上市公司普通股股東的淨利潤總額發生重大變化主要受業績下滑影響。
公司主要品種參芎葡萄糖注射液未能進入2019年8月新版國家醫保目錄,並受各地輔助用藥和重點用藥監控目錄相關政策的影響,初期外包、代理商處於謹慎觀望狀態,需求大幅下滑,2019年第四季度銷售收入相比2018年同期銷售收入下降超過90%。2020年產品進入了大多數省份的省醫保目錄(過渡期1-3年),外包、代理商的心態逐步穩定,公司聚焦於開拓等級醫院、民營醫院、縣域及以下醫療市場。預計2020年產品銷售將會恢復穩定,未來2-3年略有下降或保持平穩。
另外公司主要品種欖香烯乳狀注射液在2019年新版國家醫保目錄支付範圍內限定在“限癌性胸腹水的胸腔內或腹腔內注射治療”,縮窄了產品在臨牀中的使用範圍,並受其他相關政策的影響,2019年第四季度銷售收入相比2018年同期銷售收入下降超過60%。上述公司兩個主要品種的銷售收入大幅降低,對公司整體經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.